Abstract
Introduction
This analysis examines the historical and forecast performance for King in the
prescription pharmaceutical sector. The profile encompasses global company
strategy, portfolio and pipeline analysis and assessment of financial
performance, with 1-6 year sales forecasts for key drugs. An interactive
forecasting and analysis tool provides continually updated quantitative and
qualitative information.
Key reasons to purchase this research
- Benchmark King' s performance against key rivals in the prescription
pharmaceutical sector
- Assess the impact of the acquisition of Alpharma on King' s forecast
performance
- Analyze how the invalidation of King' s Altace and Skelaxin patents will
affect the company' s revenue performance over 200814
| 
View Cart
